Final results of a phase I study of the Heat Shock Protein 90 inhibitor Alvespimycin (17-DMAG) in patients with advanced, solid tumours
Session type: Poster / e-Poster / Silent Theatre session
1The Institute of Cancer Research, Sutton, UK, 2The Royal Marsden Hospital, Sutton, UK, 3Cancer Research UK, London, UK, 4N. Ireland Cancer Clinical Trials Unit, Belfast, UK
Method and Results
Alvespimycin [17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)] inhibits N-terminal ATPase activity of Heat Shock Protein 90 (HSP90).